^
    Back
    Association details:
    Biomarker:CD19 positive
    Cancer:B Acute Lymphoblastic Leukemia
    Drug Class:T-lymphocyte cell therapy
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: C3 – Early Trials
    New
    Source:
    EHA 2022
    Title:

    DONOR-DERIVED CD19 CAR-T CELLS AND CHEMOTHERAPY PLUS DONOR LYMPHOCYTE INFUSION IN THE TREATMENT OF RECURRENT CD19+ B-ALL AFTER ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION

    Published date:
    05/12/2022
    Excerpt:
    To compare the efficacy of donor derived CD19 car T cells and chemotherapy plus donor lymphocyte infusion in the treatment of recurrent CD19 positive B-ALL...The rates of complete remission (77.3%) in the CAR-T group were significantly higher than those in the Chemo- DLI group (38.1%) ; The 1- and 2-year leukemia-free survival(LFS) in the CAR-T group and Chemo-DLI group were 54.5% vs 9.5%, 45.5% vs 4.8% , respectively. The 1- and 2-year overall survival(OS) in the CAR-T group and Chemo-DLI group were 68.2% vs 19% , 63.6%vs 9.5%, respectively. Compared with chemotherapy plus DLI, donor-derived CD19 CAR-T is more effective and safe in the treatment of recurrent B-ALL...